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Abstract
Background: Ligand-bound estrogen receptor α (ERα) and estrogen receptor β (ERβ) modulate
AP-1-dependent transcription via protein-protein interactions on DNA, in a manner that depends
on the type of cells and the subtype of ER. We present here evidence for an additional mechanism
by which ERs modulate the transcriptional activity of AP-1.
Results: We show that ERs located in the cytoplasm efficiently activate transcription at AP-1 sites
in response to 17β-estradiol, while ERs present in the nucleus repress transcription under the same
conditions. 17β-estradiol-induced activation of the coll-73-luc reporter correlated with
cytoplasmic localization of various ERα and ERβ mutant receptors, and was inhibited in the
presence of the full estrogen antagonist ICI 182,780 and the MAP-kinase inhibitor UO126. We also
show that the selective estrogen receptor modulator (SERM) tamoxifen is as potent as 17β-
estradiol in inducing activation of AP-1 when ERα is present in the cytoplasm.
Conclusions: These results suggest that non-genomic signalling is involved in the mechanism by
which ERα and ERβ influence AP-1-dependent transcription. We have previously shown that Stat3
and Stat5 are targeted by non-genomic actions of ERs, and the results presented here allow us to
conclude that ERs bound to 17β-estradiol mediate the transcriptional activation of promoters
regulated by AP-1 and by Stat proteins via different combinations of signal transduction pathways.
Our observations thereby provide new insights into the mechanisms by which ERs act at alternate
response elements, and suggest a mechanism by which tamoxifen exerts its action as a tissue-
selective agonist.
Background
Estrogen is a key regulator of growth, differentiation and
function in a broad range of target tissues, including the
male and female reproductive tracts, mammary gland,
bone, brain and the cardiovascular system. The biological
effects of estrogen are mediated through estrogen receptor
α (ERα) and estrogen receptor β (ERβ), which belong to a
large superfamily of nuclear receptors that act as ligand-
activated transcription factors. These receptors share a
well-conserved DNA-binding domain (DBD) and a struc-
turally conserved ligand-binding domain (LBD). The N-
terminal domains of these receptors, on the other hand,
do not resemble each other [1,2]. The classical mecha-
nism of activation of ERs depends on ligand binding to
the receptors, after which the receptors dimerize and bind
to estrogen response elements (EREs) located in the pro-
moters of estrogen-responsive genes [3]. Ligand binding
also induces a conformational change within the LBD of
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the receptors, and this conformational change allows co-
activator proteins to be recruited [4].
ERs may also regulate gene expression in the absence of
DNA-binding by modulating the activities of other tran-
scription factors via protein-protein interactions on DNA.
This mechanism is referred to as cross-talk and is common
for several nuclear receptors [5]. For example, ligand-
bound ERs upregulate and downregulate transcription
from genes that contain AP-1 sites, binding sites for the
Jun/Fos complex, in a manner that depends on the type of
cells and the subtype of ER [6-9]. Furthermore, ERα and
ERβ efficiently potentiate the transcriptional activity of
signal transducer and activator of transcription (Stat) 5 b
when Stat5b is bound to the β-casein promoter following
prolactin stimulation [10]. In addition, specific amino
acids within the ER DBD are important for transcriptional
cross-talk on promoters regulated by AP-1 and by Stat5b
[11].
The rapid effects of estrogen observed in the mammary
gland, bone, brain and the cardiovascular system suggest
that estrogen also exerts non-genomic effects, possibly via
membrane-associated ERs that are linked to signal trans-
duction proteins [12]. For example, estrogen rapidly acti-
vates the MAP-kinase, Src-kinase, and PI3-kinase
signalling pathways [13-16].
We have previously shown that 17β-estradiol-bound ERα
and ERβ efficiently induce transactivation of promoters
regulated by Stat proteins via signal transduction path-
ways [17]. In this study, we present evidence that also AP-
1 is a downstream target of non-genomic actions of ERs.
We show that ERα and ERβ located in the cytoplasm effi-
ciently induce transcriptional activation of the AP-1-regu-
lated collagenase promoter in response to 17β-estradiol,
while ERs present in the nucleus repress promoter activity
under the same conditions. We also show that the cellular
localization of the respective receptor subtypes deter-
mines the response to selective estrogen receptor modula-
tors (SERMs) at AP-1 sites, and we suggest that this
contributes to the tissue-specific actions of SERMs
observed in vivo. Finally, we conclude that the combina-
tions of signal transduction pathways required for 17β-
estradiol-induced activation of AP-1 is different from that
required for activation of Stat proteins.
Results
Cytoplasmic localization of ERα and ERβ correlates with a 
reversed response by 17β-estradiol on the collagenase 
promoter
We have previously shown that ERs located in the cyto-
plasm efficiently induce transactivation of Stat-regulated
promoters via non-genomic signalling [17]. We have used
an ERα variant with disturbed localization (NLSA) (Fig.
1A and [18]) to analyse whether the cellular localization
of ER affected transcription from the AP-1-regulated colla-
genase promoter. Fig. 1B shows that the coll-73-luc
reporter [6] was induced 3-fold in response to 17β-estra-
diol upon co-transfection with NLSA into HC11 mouse
mammary epithelial cells, while the wild-type receptor
repressed the reporter 2-fold under the same conditions.
These results encouraged us to analyse whether ERβ dis-
played a similar activity on the collagenase promoter
when ERβ is present in the cytoplasm. We therefore chose
to use an N-terminal deletion mutant of ERβ (ERβ 148-
530 Flag) that we knew was predominantly present in the
cytoplasm of cells (Fig. 1A). It is not known why ERβ 148-
530 Flag remains located in the cytoplasm. Interestingly,
however, a corresponding deletion mutant comprising a
Flag tag upstream of the N-terminus (ERβ Flag 148-530)
showed nuclear staining (Fig. 1A). We found that the cyto-
plasmic ERβ 148-530 Flag variant activated the coll-73-luc
reporter 2.5-fold in response to 17β-estradiol, while ERβ
Flag 148-530 located in the nucleus acted like the wild-
type receptor and repressed the reporter 2-fold under the
same conditions (Fig. 1B). These results show a perfect
correlation between the cellular localization of the recep-
tor and its activity on the collagenase promoter.
NLSA induces transactivation of the Stat-regulated β-
casein promoter via non-genomic signalling [17]. Fig. 1C
shows that the β-casein reporter [19] was induced 5-fold
and 6-fold, respectively, in response to 17β-estradiol
upon co-transfection with NLSA or ERβ 148-530 Flag into
HC11 cells, while ER wild type receptors and ERβ Flag
148-530 only showed weak responses on the reporter.
These results strongly suggest that ERβ 148-530 Flag, like
NLSA, acts on the promoter via non-genomic signalling.
In summary, cytoplasmic localization of ERα and ERβ cor-
relates with a reversed response by 17β-estradiol on the
collagenase promoter, suggesting that AP-1 can be
induced to activate transcription via non-genomic actions
of ERs, in a manner similar to that of Stat proteins.
Disruption of the ERβ DBD results in an altered 
localization of the receptor and transactivation of the 
collagenase promoter in the presence of 17β-estradiol
We recently showed that the introduction of various point
mutations into the ERβ DBD results in an altered response
by ER ligands on the collagenase promoter [11]. Fig. 2A
shows that the coll-73-luc reporter was induced 3-fold in
response to 17β-estradiol upon co-transfection with an
ERβ mutant comprising a disruption of the second zinc
binding motif (C201A/C204A) into HC11 cells, while the
wild-type receptor repressed the reporter 2-fold under the
same conditions. Fig. 2A also shows that the Stat-regu-
lated β-casein reporter was induced 2.5-fold in response
to 17β-estradiol upon co-transfection with C201A/
C204A. We have previously shown that C201A/C204A isNuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/3
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Cytoplasmic variants of ERα and ERβ display reversed activity at an AP-1 response element Figure 1
Cytoplasmic variants of ERα and ERβ display reversed activity at an AP-1 response element. (A) HC11 cells 
were transfected with expression vectors for ERα wt, NLSA, deleted in the hinge domain (∆245-307), ERβ wt, ERβ Flag 148-
530 or ERβ 148-530 Flag. The cellular localization of the receptor proteins was analysed by indirect immunofluorescence as 
described in Experimental Procedures. HC11 cells were transiently co-transfected with (B) 500 ng coll-73-luc reporter gene 
or (C) 1 µg β-casein reporter gene and 200 ng of ERα wt, NLSA, ERβ wt, ERβ Flag 148-530 or ERβ 148-530 Flag. Cells were 
treated with either no hormone (NH) or 10-8 M 17β-estradiol (E2), and the reporter activity was analysed 24 hours after treat-
ment. Luciferase activity was normalised using β-gal as an internal control. Data are representative of at least three independ-
ent experiments performed in duplicate. Mean and ± SD are shown.
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ERβ structurally disrupted in the DBD re-localizes to the cytoplasm and induces AP-1 activity in the presence of 17β-estradiol Figure 2
ERβ structurally disrupted in the DBD re-localizes to the cytoplasm and induces AP-1 activity in the presence 
of 17β-estradiol. (A) HC11 cells were transiently co-transfected with 500 ng coll-73-luc reporter gene or 1 µg β-casein 
reporter gene and 200 ng of ERβ wt or C201A/C204A. Cells were treated with either no hormone (NH) or 10-8 M 17β-estra-
diol (E2), as indicated, and the reporter activity was analysed 24 hours after treatment. Luciferase activity was normalised using 
β-gal as an internal control. Data are representative of at least three independent experiments performed in duplicate. Mean 
and ± SD are shown. (B) HC11 cells were transfected with expression vectors for ERβ wt or C201A/C204A. Cells were 
treated with either no hormone (NH) or 10-8 M 17β-estradiol (E2), as indicated, and the cellular localization of the receptor 
proteins was analysed 24 hours after treatment by indirect immunofluorescence as described in Experimental Procedures.
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unable to potentiate the transcriptional activity of prolac-
tin-activated Stat5b through cross-talk in the nucleus [11].
Thus, the response by 17β-estradiol indicates that the
mutant receptor induces transactivation of the β-casein
promoter through a distinct mechanism, independently
of pre-activated Stat proteins.
The similarity between the results shown in Fig. 2A and
the results shown in Fig. 1 prompted us to analyse the cel-
lular localization of C201A/C204A. We found that the
mutant receptor re-localized to the cytoplasm of cells
upon treatment with 17β-estradiol, while the localization
of the wild-type receptor, as expected, was not affected
(Fig. 2B). We also noted that all of the previously
described ERβ DBD mutants that displayed an altered
response by ER ligands on the collagenase promoter [11]
re-localized to the cytoplasm upon treatment with 17β-
estradiol and, furthermore, induced transcription from
the β-casein promoter more efficiently than the wild-type
receptor (data not shown). In summary, the introduction
of various point mutations into the ERβ DBD results in an
altered localization of the receptor in the presence of 17β-
estradiol. The cytoplasmic localization correlates perfectly
with efficient transactivation of promoters regulated by
AP-1 and by Stat proteins, and this strongly suggests that
non-genomic signalling is involved.
The cellular localization of ERα and ERβ determines the 
response to ER ligands on the collagenase promoter
We analysed the ability of ER to modulate AP-1-depend-
ent transcription via non-genomic signalling in the pres-
ence of various ER ligands. Fig. 3A shows that the coll-73-
luc reporter was induced 3-fold in response to the natural
agonist 17β-estradiol, the non-steroidal agonist diethyl-
stilbestrol (DES), the ERα selective agonist propyl pyra-
zole triol (PPT) [20] and the synthetic compound 4-
estren-3a,17β-diol (estren) upon co-transfection with
NLSA into HC11 cells. Interestingly, while the selective
estrogen receptor modulator (SERM) tamoxifen induced
transcription 2.5-fold, the SERMs raloxifene, nafoxiden
and idoxifen showed no effect on the promoter. The full
estrogen antagonist ICI 182,780 was unable to induce
transcription and, furthermore, completely inhibited the
17β-estradiol-induced response on the coll-73-luc
reporter.
The activity of ERβ 148-530 Flag on the coll-73-luc
reporter in the presence of the various ER ligands is shown
in Fig. 3B. The reporter was induced 3-fold in response to
17β-estradiol and DES, while the ERα selective ligand PPT
showed no affect, and estren induced the reporter 2-fold.
ERβ 148-530 Flag did not activate transcription in the
presence of any of the SERMs, tamoxifen, raloxifene,
nafoxiden or idoxifen, or the full estrogen antagonist ICI
182,780 and, furthermore, the 17β-estradiol-induced
response on the reporter was completely inhibited in the
presence of tamoxifen and the presence of ICI 182,780.
Notably, C201A/C204A showed responses on the coll-73-
luc reporter in the presence of the various ER ligands
tested that are similar to those of ERβ 148-530 Flag (data
not shown).
A consensus reporter construct including two AP-1 bind-
ing sites (TRE-tk-luc) was co-transfected together with
NLSA or ERβ 148-530 Flag into HC11 cells in order to
confirm that the ER-dependent activation of the authentic
coll-73-luc reporter is mediated through the AP-1-binding
site in the collagenase promoter. Fig. 3C shows that simi-
lar results were obtained using the TRE-tk-luc reporter as
were obtained with the coll-73-luc reporter: NLSA acti-
vated transcription in response to 17β-estradiol and
tamoxifen, but not in response to ICI 182,780, while ERβ
148-530 Flag only activated transcription in response to
17β-estradiol. This confirms that AP-1 is the target tran-
scription factor of NLSA and ERβ 148-530 Flag actions.
We can conclude that the stimulation of reporter activity
depended on transfected ER, since cells transfected with
only the reporter showed no induction of transcription in
the presence of ER ligands (data not shown).
The activities of ER wild-type receptors in the presence of
the various ER ligands are shown in Fig. 3D. The coll-73-
luc reporter was repressed 2-fold in response to 17β-estra-
diol, DES and estren, while transcription was induced 2.5-
fold in the presence of the full estrogen antagonist ICI
182,780 upon co-transfection with ERα or ERβ into HC11
cells. As expected, only ERα repressed the reporter in
response to PPT. Interestingly, however, only ERβ wild-
type activated transcription in response to SERMs: the
reporter was induced by a factor of 2.5 in the presence of
tamoxifen, raloxifene, nafoxiden or idoxifen. In summary,
ERs located in the cytoplasm show responses to SERMs on
the AP-1-regulated collagenase promoter that are different
from those shown when the ERs were present in the
nucleus, and the two ER subtypes differ in their ligand
preferences.
Signal transduction pathways involved in 17β-estradiol-
induced activation of AP-1
The coll-73-luc reporter was co-transfected together with
cytoplasmic ER variants into HC11 cells and the stimula-
tion of reporter activity was analysed in the presence of
inhibitors of the MAP-kinase and PI3-kinase signalling
pathways in order to analyse what signal transduction
pathways are required for 17β-estradiol-induced activa-
tion of AP-1. Fig. 4A shows that 17β-estradiol-induced
activation of the reporter in the presence of NLSA, ERβ
148-530 Flag or C201A/C204A was completely inhibited
when the cells were pretreated with the MAP-kinase
kinase (MEK) 1/2 inhibitor, UO126, while the activityNuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/3
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Ligand-dependent ER actions at an AP-1 response element Figure 3
Ligand-dependent ER actions at an AP-1 response element. HC11 cells were transiently co-transfected with 500 ng 
coll-73-luc reporter gene and (A) 200 ng of NLSA or (B) ERβ 148-530 Flag. Cells were treated with either no hormone (NH), 
10-8 M 17β-estradiol (E2), 10-7 M DES, 10-7 M PPT, 10-7 M estren, 10-7 M tamoxifen (OHT), 10-7 M raloxifene (Ral), 10-7 M 
idoxifene (Idox), 10-7 M nafoxidene (Nafox) or 10-7 M ICI 182,780 (ICI), as indicated, and the reporter activity was analysed 24 
hours after treatment. Luciferase activity was normalised using β-gal as an internal control. Data are representative of at least 
three independent experiments performed in duplicate. Mean and ± SD are shown. (C) HC11 cells were transiently co-trans-
fected with 500 ng TRE-tk-luc reporter gene and 200 ng of NLSA or ERβ 148-530 Flag. Cells were treated with either no hor-
mone (NH), 10-8 M 17β-estradiol (E2), 10-7 M tamoxifen (OHT) or 10-7 M ICI 182,780 (ICI), as indicated, and further assayed as 
described in A and B. (D) HC11 cells were transiently co-transfected with 500 ng coll-73-luc reporter and 200 ng of ERα wt or 
ERβ wt. Cells were treated and analysed as described in A and B.
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Intact MAP-kinase activity is important for non-genomic actions of ERs at AP-1 sites Figure 4
Intact MAP-kinase activity is important for non-genomic actions of ERs at AP-1 sites. (A) HC11 cells were tran-
siently co-transfected with 500 ng coll-73-luc reporter gene and 200 ng of NLSA, ERβ 148-530 Flag or C201A/C204A. Cells 
were pretreated with 10 µM UO126 or 10 µM LY294002 for one hour before the addition of 10-8 M 17β-estradiol (E2), and 
the reporter activity was analysed 6 hours after treatment. (B) SYF cells were transiently co-transfected with 500 ng coll-73-
luc reporter gene and 200 ng of NLSA, ERβ 148-530 Flag or C201A/C204A. Cells were treated with either no hormone (NH), 
10-8 M 17β-estradiol (E2) or 10-7 M tamoxifen (OHT), and the reporter activity was analysed 24 hours after treatment. Luci-
ferase activity was normalised using β-gal as an internal control. Data are representative of at least three independent experi-
ments performed in duplicate. Mean and ± SD are shown.
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was not significantly affected in the presence of the PI3-
kinase inhibitor, LY294002.
The involvement of Src-kinase was analysed by transient
transfection of embryonic fibroblast cells derived from
Src-kinase -/- mice (SYF cells) [21]. The coll-73-luc
reporter was activated in response to 17β-estradiol in SYF
cells upon co-transfection with NLSA, ERβ 148-530 Flag
or C201A/C204A (Fig. 4B), demonstrating that Src-kinase
is not involved in the signalling pathway that regulates
17β-estradiol-induced activation of AP-1. Furthermore,
only NLSA activated transcription in the presence of
tamoxifen, resembling the response observed in HC11
cells. In summary, intact MAP-kinase activity is essential
for 17β-estradiol-induced activation of AP-1, while nei-
ther PI3-kinase nor Src-kinase is involved in this effect. In
contrast, however, 17β-estradiol-induced activation of
Stat proteins does require all three pathways to be intact
[17]. Thus, we conclude that the combinations of signal
transduction pathways required for 17β-estradiol-induced
transactivation of promoters regulated by AP-1 and by
Stat proteins are different.
Discussion
We have shown in this study that the cytoplasmic locali-
zation of ERs correlates with efficient transactivation of
the AP-1-regulated collagenase promoter in response to
17β-estradiol, while ERs present in the nucleus repress AP-
1 activity under the same conditions. We suggest that this
reversed 17β-estradiol-induced response is due to the
ability of ERs to induce AP-1 activity via non-genomic sig-
nalling when they are present in the cytoplasm.
It is generally believed that ER-mediated regulation of AP-
1-dependent transcription results from protein-protein
interactions on the promoter. ERα interacts with c-Jun in
vitro [6,9,22] and the domain required for this interaction
has been mapped to amino acids 259-302, which are
located in the hinge domain of the receptor [22]. The find-
ing that NLSA, which lacks the entire hinge domain, effi-
ciently activated the coll-73-luc reporter in response to
17β-estradiol (Fig. 1B) suggests that NLSA induces AP-1
activity through a distinct mechanism, independently of
physical interaction with c-Jun on DNA. Furthermore, the
coll-73-luc reporter was similarly induced in response to
17β-estradiol upon co-transfection with a cytoplasmic
ERβ variant (ERβ 148-530 Flag) (Fig. 1B), suggesting that
non-genomic signalling is involved. The finding that ERβ
148-530 Flag also activated the Stat-regulated β-casein
reporter in response to 17β-estradiol (Fig. 1C), as has
been previously shown for NLSA [17], supports our
hypothesis that the deletion mutant acts via non-genomic
signalling in the cytoplasm. In contrast, however, a corre-
sponding deletion mutant comprising a Flag tag upstream
of the N-terminus (ERβ Flag 148-530) was present in the
nucleus, and hence was unable to activate the coll-73-luc
reporter via non-genomic signalling (Fig. 1B). Our results
suggest that cytoplasmic re-localization of ERs and subse-
quent signaling through cytoplasmic signal transduction
pathways is an additional mechanism by which ERs are
able to modulate the transcriptional activity of AP-1. It
should be noted that there are discrepancies in the litera-
ture regarding ER action at AP-1 sites. In accordance with
our results, repression of the collagenase promoter in the
presence of ERα and ERβ bound to 17β-estradiol has been
described [9,23,7]. In contrast, however, other studies
have shown that ERα bound to 17β-estradiol induces acti-
vation of AP-1 [6-8]. Differences in experimental condi-
tions could explain some of the discrepancies obtained
with ERs acting in the nucleus.
We recently reported that the introduction of various
point mutations into the ERβ DBD results in an altered
response by ER ligands on the collagenase promoter [11].
The results presented here suggest a mechanism for this
phenomenon. Disruption of the second zinc binding
motif (as in the ERβ mutant C201A/C204A) resulted in
altered localization of the receptor in the presence of 17β-
estradiol. The coll-73-luc reporter was also efficiently acti-
vated under these conditions (Fig. 2A and 2B). Further-
more, C201A/C204A activated the β-casein reporter in
response to 17β-estradiol more efficiently than the wild-
type-receptor, suggesting that C201A/C204A acts via non-
genomic signalling in a manner similar to that in which
both NLSA and ERβ 148-530 Flag act. Notably, all of the
ERβ DBD mutants described in [11] that reversed the
response to 17β-estradiol on the collagenase promoter
acted in the same manner (data not shown). Thus, we sug-
gest that the introduction of various point mutations into
the ERβ DBD enables the receptor to induce AP-1 activity
via non-genomic signalling, due to re-localization of the
receptor to the cytoplasm in the presence of 17β-estradiol.
This phenomenon is not restricted to HC11 cells, since
similar results were obtained in the human breast cancer
cell line MCF-7, the human uterine cell line Ishikawa and
the human hepatic cell line HepG2 (data not shown). In
COS-7 cells, on the other hand, ERβ 148-530 Flag and the
various ERβ DBD mutants, although present in the cyto-
plasm, only showed weak responses on the coll-73-luc
reporter in the presence of 17β-estradiol, while NLSA effi-
ciently activated the reporter (data not shown). These
results are in accordance with our previous results [17]
and suggest that non-genomic signalling via ERβ is not as
efficient in COS-7 cells as in HC11, MCF-7, Ishikawa,
HepG2 and SYF cells, while ERα is active in all cells tested.
A natural splice variant of ERβ lacking the C-terminal part
of the DBD (ERβδ3) localizes to discrete nuclear spots and
activates transcription at AP-1 sites in the presence of 17β-
estradiol [24]. This agrees with the results presented here.Nuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/3
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Interestingly, however, we found that our ERβ DBD
mutants, including one that lacked the entire DBD, not
only localized to discrete nuclear spots, but also re-local-
ized to the cytoplasm upon 17β-estradiol treatment. Fur-
thermore, it has been suggested that a similar
supernormal activity of an ERα DBD mutant (K206A) on
the collagenase promoter arises from the inability of 17β-
estradiol-bound K206A to recruite a putative co-repressor
complex to the promoter. This inability would allow for
effective target gene transcription [25]. However, the find-
ing that ERβ 148-530 Flag efficiently activated the coll-73-
luc reporter in response to 17β-estradiol (Fig. 1B) demon-
strates that the activity is not unique for receptors that
have mutations within the DBD, and which would there-
fore be unable to interact with such a co-repressor com-
plex through the DBD. Rather, our results suggest that ERβ
148-530 Flag and the various ERβ DBD mutants described
in [11] induce AP-1 activity via non-genomic signalling
when present in the cytoplasm. We can not, however, rule
out additional mechanisms by which ERs that have muta-
tions within the DBD may act at AP-1 sites.
The ability of ER to modulate AP-1-dependent transcrip-
tion in the presence of SERMs is specific for a particular
subtype of ER, and this ability depends on the cellular
localization of the receptor. While ERα wild-type was
inactive in the presence of SERMs, ERβ wild-type activated
the coll-73-luc reporter in response to tamoxifen,
raloxifene, idoxifene and nafoxidene (Fig. 3D). In con-
trast, however, NLSA activated transcription in response
to tamoxifen, while ERβ 148-530 Flag and C201A/C204A
were inactive in the presence of all SERMs tested (Fig. 3A
and 3B). Notably, the inability of C201A/C204A to acti-
vate the coll-73-luc reporter in response to tamoxifen is
not due to persistent nuclear localization of the protein,
since the receptor re-localized to the cytoplasm also in the
presence of estrogen antagonists (data not shown). Thus,
tamoxifen-induced activation of AP-1 via non-genomic
signalling appears to be specific for ERα. These results pro-
vide new insights into the mechanisms that underlie the
tissue-specific actions of SERMs observed in vivo. Non-
genomic actions exerted by tamoxifen at AP-1 sites prob-
ably contribute to some of the responses, such as, for
example, the responses in target tissues where pools of
ERα are localized to the cytoplasm, such as the mammary
gland, bone, brain and the cardiovascular system [26-31].
Several genes involved in cell proliferation are regulated
by AP-1, and thus the non-genomic actions of ERs at these
sites may be highly important, and they may contribute to
phenomena such as tamoxifen-resistance in ER-positive
breast cancer cells. The full estrogen antagonist ICI
182,780 completely inhibited 17β-estradiol-induced acti-
vation of the coll-73-luc reporter in the presence of cyto-
plasmic ERs (Fig. 3A and 3B), and this finding agrees with
our previous results showing that non-genomic actions of
ERs are inhibited in the presence of ICI 182,780 [17]. It
has been suggested that the synthetic compound estren
distinguishes between genomic and non-genomic actions
of ERα [32]. Importantly, however, we found that the coll-
73-luc reporter was repressed in the presence of ER wild-
type receptors and estren (Fig. 3D), and we found that
estren can induce AP-1-dependent transcription via non-
genomic signalling (Fig. 3A and 3B). Hence, estren affects
the activity of ERs present both in the nucleus and in the
cytoplasm.
MAP-kinase activity induced by 17β-estradiol results in an
enhanced DNA-binding activity of AP-1 [33] and 17β-
estradiol-induced expression of cyclin D1 depends both
on the AP-1 site within the promoter and on an intact
MAP-kinase activity [34]. We have shown that an intact
MAP-kinase pathway is required for 17β-estradiol-
induced activation of the coll-73-luc reporter, and we
have shown that the activity does not depend on an intact
PI3-kinase activity (Fig. 4A). These results agree with those
of Dos Santos and those of Marino. Furthermore, Src-
kinase is not required for 17β-estradiol-induced activa-
tion of AP-1, as shown by the intact responses on the coll-
73-luc reporter upon co-transfection of cells devoid of Src-
kinase with NLSA, ERβ 148-530 or C201A/C204A (Fig.
4B). We have previously shown that 17β-estradiol-
induced transactivation of Stat-regulated promoters
requires intact MAP-kinase, PI3-kinase and Src-kinase
activities [17]. Thus, our results suggest that distinct signal
transduction pathways are involved in ER-dependent
non-genomic actions targeting promoters regulated by
AP-1 and by Stat proteins. The transcriptional activity of c-
Jun depends only on serine phosphorylation [35]. How-
ever, tyrosine phosphorylation is a pre-requisite for induc-
ing nuclear translocation and DNA-binding activity of Stat
proteins [36], and this may explain why Src-kinase and
PI3-kinase [16] are required in the pathway targeting Stat-
regulated promoters. Furthermore, the inability of 17β-
estradiol-bound ERs to induce Src-kinase activity in the
presence of estrogen antagonists [13] might explain our
previous finding that 17β-estradiol-induced activation of
Stat proteins is inhibited in the presence of tamoxifen
[17]. In contrast, however, NLSA induced AP-1 activity in
response to tamoxifen (Fig. 3A), independently of Src-
kinase activity (Fig. 4C). Thus, the set of signal transduc-
tion proteins available in a given cell probably determines
which target transcription factors are activated by ligand-
bound ERs present in the cytoplasm, and hence the cellu-
lar outcome.
Conclusions
Our results show that ER modulates AP-1-dependent tran-
scription through two distinct mechanisms: via protein-
protein interactions on DNA; and via non-genomic
actions. The mechanism used depends on the cellularNuclear Receptor 2004, 2 http://www.nuclear-receptor.com/content/2/1/3
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localization of the receptor. In addition to the more exten-
sively studied cross-talk on DNA, additional non-genomic
actions might be very important in target tissues in which
membrane-associated ERs are found. These non-genomic
actions probably contribute to the overall physiological
responses mediated by ligand-bound ERs.
Methods
Plasmids
The coll-73-luc reporter was provided by Peter Kushner
(University of California, San Francisco, USA) [6], the β-
casein (-344 to -1) luciferase reporter was provided by
Bernd Groner (Frankfurt, Germany) [19] and the TRE-tk-
luc reporter by Sam Okret (Karolinska Institutet, Hud-
dinge, Sweden). The following plasmids have been
described previously: mouse ERα expression vector pMT2-
MOR [37], pMT2-MOR ∆245-307 (NLSA) [18] and
human ERβ expression vector pSG5-ERβ [38]. The pSG5-
ERβ DBD mutant (C201A/C204A) and the N-terminal
deletion mutants (ERβ Flag 148-530 and ERβ 148-530
Flag) were constructed by recombinant PCR and verified
by automated sequencing.
Hormones and signal transduction inhibitors
17β-estradiol, 4-hydroxy tamoxifen, nafoxiden, diethyl-
stilbestrol and genistein were purchased from Sigma. The
full estrogen antagonist ICI 182,780 and the ERα selective
agonist PPT were purchased from Tocris Cookson Inc.,
MO, USA. 4-estren-3α,17β-diol was purchased from Ster-
aloids, RI, USA. The MEK1/2 inhibitor, UO126, and the
PI3-kinase inhibitor, LY294002, were purchased from
Cell Signalling Technology, MA, USA. Raloxifene and
idoxifene were obtained from Karo Bio AB.
Cell culture and transient transfection techniques
HC11 cells were cultured in RPMI 1640 medium (Life
Technologies, Inc., Buckinghamshire, UK) supplemented
with 10% FBS, 5 µg/ml epidermal growth factor (human
recombinant; Sigma) and insulin (Actrapid; Novonord-
isk, Denmark). SYF cells (purchased from ATCC™) were
cultured in Dulbecco's modified Eagle's medium
(DMEM) (Life Technologies, Inc.) supplemented with
10% fetal bovine serum (FBS) (Life Technologies, Inc.).
For transient transfection assays, cells were seeded in
DMEM free of phenol-red (Life Technologies, Inc.) sup-
plemented with 5% dextran-charcoal-stripped (DCS) FBS
(HyClone Laboratories, Inc., UT, USA) in 24-well microti-
tre plates 24 hours before transfection. Cells were trans-
fected with reporter plasmid, pCMV-βGal plasmid as an
internal control and various expression plasmids, as indi-
cated in the figure legends, using lipofectamine (Life Tech-
nologies, Inc.). Incubation with lipofectamine-DNA
complexes was carried out for 5 hours in serum-free
medium. Fresh medium was added after the transfection
and the cells were incubated with hormones, as indicated
in the figures, for 16 hours. The cells were harvested in
lysis buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 150
mM NaCl and 0.65% NP-40) and extracts were assayed
for luciferase and β-galactosidase activity in a microplate
reader (Lucy-1; Anthos, Salzburg, Austria). For immun-
ofluorescence studies, HC11 cells were seeded onto cover-
slips placed in 6-well tissue culture plates in phenol-red
free DMEM supplemented with 5% DCS FBS. Cells were
transfected with lipofectamine as described above and
then processed for histological studies, as previously
described [17]. ERα proteins were detected using the pol-
yclonal antibody H-184 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA). ERβ proteins were detected using an ERβ
polyclonal antibody (Upstate Biotechnology, Inc., Lake
Placid, NY) and a monoclonal Flag antibody (Santa Cruz
Biotechnology, Inc.). An appropriate fluorescein isothio-
cyanate (FITC)-conjugated secondary antibody (DAKO A/
S, Glostrop, Denmark) was used. Cell nuclei were stained
with 4,6-diamidino2-phenylindole (DAPI).
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